EX-99.1 2 igcex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IGC Pharma Inc UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1 - Transaction Overview On September 29, 2025, Holi Hemp LLC (“HHP”), a wholly owned subsidiary of IGC Pharma, Inc. (the “Company”), completed the disposition of certain manufacturing equipment, leasehold assets, and inventory located at its Vancouver, Washington facility (the “Vancouver Facility”) pursuant to a Sale of Assets and Manufacturing Agreement with Wellness Essentials Northwest LLC (the “Buyer”). The Buyer also assumed certain employees and short-term lease obligations. The consideration received consisted of (i) contractual rights to manufacture the Company’s products at preferential pricing through December 31, 2030, and (ii) a contingent right to receive 10 percent of net proceeds if the Buyer sells the business within five years. No cash consideration was exchanged. An independent valuation determined the aggregate fair value of consideration received to be approximately $ 2.7 million. Note 2 - Description of Pro Forma Adjustments The following pro forma adjustments are reflected: Derecognition of assets: Elimination o…
Open exhibit ↗Current Report · Items 2.01, 9.01 · 8-K
IGC Pharma, Inc.
IGCNYSE_AMERICANEQUITYCurrent
Completion of Acquisition or Disposition of Assets
Item 9.01 Financial Statements and Exhibits (b) Pro Forma Financial Information The unaudited pro forma condensed consolidated balance sheet as of June 30, 2025, and the unaudited pro forma condensed consolidated statement of operations for the three months ended June 30, 2025, reflecting the disposition described above are filed as Exhibit 99.1 and incorporated herein by reference. Exhibit No.…
Company context
IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer’s dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With more than 30 patent filings, 12 patents granted and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.